Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia

Autor: Yihan Mei, Yu Liu, Wenbing Liu, Manling Chen, Xiaoyu Liu, Shangshang Wang, Junli Mou, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang, Runxia Gu, Shaowei Qiu, Jianxiang Wang

Publikováno v: Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-15 (2024)

Abstract Besides chemotherapy and hematopoietic stem cell transplantation (HSCT), autologous T cells can also serve as a new treatment approach for AML patients. However, the features of tumor-reactive T cells and their distinctive markers still lack

Externí odkaz: https://doaj.org/article/e97357d17ad2400eafbb3881b7f30d9b

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity

Autor: Zhenzhen Wang, Yang Lu, Yu Liu, Junli Mou, Xiaoyu Liu, Manling Chen, Ying Wang, Yingxi Xu, Qing Rao, Haiyan Xing, Kejing Tang, Zheng Tian, Bing Wang, Wei Qi, Min Wang, Shaowei Qiu, Dongsheng Xiong, Jianxiang Wang

Publikováno v: Cancer Communications, Vol 43, Iss 10, Pp 1178-1182 (2023)

Externí odkaz: https://doaj.org/article/0e847548875a41cabe1da6794ef1c6ff

Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma

Autor: Baohong Luo, Yu Sun, Qinru Zhan, Yuting Luo, Yu Chen, Tongze Fu, Tiantian Yang, Lijuan Ren, Zhongpeng Xie, Xiaohua Situ, Bixia Liu, Kejing Tang, Zunfu Ke

Publikováno v: Clinical and Translational Medicine, Vol 14, Iss 1, Pp n/a-n/a (2024)

Abstract Background T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) is an immune checkpoint molecule that suppresses CD8+ T‐cell function in cancer. However, the expression profile and functional signific

Externí odkaz: https://doaj.org/article/9f05ad792a4943bc9580a5071deb2e87

Expert consensus on treatment for stage III non‐small cell lung cancer

Autor: Yi‐Long Wu, Shun Lu, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wenzhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Siyang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jiatao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jinji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Haiyan Tu, Wurong Lin, Xuchao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang

Publikováno v: Medicine Advances, Vol 1, Iss 1, Pp 3-13 (2023)

Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation

Externí odkaz: https://doaj.org/article/628a61c2e0b7401888cbceb96adb32ce

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis

Autor: Muyesar Alifu, Min Tao, Xiao Chen, Jie Chen, Kejing Tang, Yubo Tang

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

IntroductionRecent clinical trials have confirmed that anti-programmed cell death-1/ligand 1 (anti-PD-1/L1) combined with either anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-T-cell immunoreceptor with Ig and ITIM domains (TI

Externí odkaz: https://doaj.org/article/49f74df776474d4199182700d35d4f7b